The goal of treatment of essential thrombocytosis is to prevent vascular complications such as thrombotic and hemorrhagic events; this is because thrombosis and hemorrhage are the leading causes of morbidity and mortality.

Hydroxyurea is the first line cytoreductive therapy used. If not well tolerated or patient is resistance to hydroxyurea, then anagrelide is used. Hydroxyurea has been shown to reduce both the number of platelets and the number of leukocytes causing a reduction in thrombosis and myelofibrosis.